Becton, Dickinson and Company
NYSE:BDXMedical - Instruments & Supplies
+$2.36 today
- Market cap
- $58.86B
- Beta
- 0.28
- P/E (TTM)
- 35.5
- EPS (TTM)
- $4.06
- Dividend yield
- 2.60%
Volume 1.32M
Average 2.76M
BDX Sales of Investments
Cash received from selling or redeeming investments.
Becton, Dickinson and CompanyNYSE: BDX
Sales of Investments · Q4 FY2026 · quarter ended Sep 2026
Sales of investments turns negative
Q4 FY2026 sales of investments was -$7M, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $43M.
Context
- Sales of investments amounted to 0.1% of revenue in FY2026, down 1.8 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly sales of investments holds near -$7M or moves back toward the trailing-twelve-month quarterly average of $10.75M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2026
- 20M USD
- Year-over-year change
- -95.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 20M | -95.3% |
| FY2025 | 2025-09-30 | 422M | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Sales of Investments vs competitors
How BDX compares with its peers on the latest reported figures
- BDX's LTM Sep 2026 sales of investments of $43M is the 3rd largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +110.5% is the 3rd highest of 5, against a peer median of +107.1%.
- Sales of investments amounts to 0.2% of revenue for BDX, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $8.3B | -0.5% | +3.3% | 22.1% | |
| LTM Mar 2026 | $56.36M | +211.2% | +67.1% | 56.5% | |
| LTM Sep 2026 | $43M | +110.5% | — | 0.2% | |
| LTM Jun 2026 | $3M | +114.3% | -73.0% | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | +100.0% | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BDX) | $0 | +107.1% | +3.3% | 0.0% | |
Competitors are the stored peer set for BDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Net Income | 1.78B | 1.53B | 1.71B | 1.68B | 1.15B |
| Depreciation & Amortization | 2.23B | 2.29B | 2.29B | 2.46B | 2.24B |
| Deferred Income Tax | (120M) | (622M) | (211M) | (474M) | 0 |
| Stock-Based Compensation | 233M | 259M | 247M | 258M | 0 |
| Change in Working Capital | (1.39B) | (630M) | 293M | (800M) | (50M) |
| Accounts Receivables | 32M | (290M) | (453M) | 71M | 0 |
| Inventory | (631M) | (15M) | 98M | (410M) | 0 |
| Accounts Payables | (473M) | (517M) | 625M | (185M) | 0 |
| Other Working Capital | (322M) | 192M | 23M | (276M) | (50M) |
| Other Non-Cash Items | (94M) | 164M | (522M) | 306M | 272M |
| Operating Cash Flow | 2.63B | 2.99B | 3.8B | 3.43B | 3.61B |
| Capital Expenditures | (973M) | (874M) | (725M) | (760M) | (672M) |
| Acquisitions (Net) | (2.07B) | 540M | (3.92B) | 0 | (22M) |
| Purchases of Investments | 0 | 0 | (421M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 422M | 20M |
| Other Investing Activities | (188M) | (382M) | (444M) | (480M) | (336M) |
| Investing Cash Flow | (3.23B) | (716M) | (5.51B) | (818M) | (1.01B) |
| Debt Repayment | (78M) | (722M) | 3.78B | (1.33B) | (2.41B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (500M) | 0 | (500M) | (1B) | (2.43B) |
| Dividends Paid | (1.08B) | (1.11B) | (1.1B) | (1.2B) | (1.16B) |
| Other Financing Activities | 1.07B | (121M) | (88M) | (87M) | 3.84B |
| Financing Cash Flow | (591M) | (1.96B) | 2.09B | (3.62B) | (2.16B) |
| Effect of Forex Changes | (45M) | 5M | 4M | 0 | 7M |
| Net Change in Cash | (1.23B) | 322M | 375M | (1.01B) | 233M |
| Free Cash Flow | 1.66B | 2.12B | 3.07B | 2.67B | 2.93B |
Becton, Dickinson and Company
NYSE:BDX
Intrinsic Alpha fair value
Locked
Current Price
$216.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.